Eslicarbazepine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and TLV (Sweden) recommended or restricted eslicarbazepine, while PBAC (Australia) did not recommend it.
Assessment has run over 11.5 years, from 18 Jan 2010 at SMC (Scotland) to 2021 at PBAC (Australia).
AWMSG (Wales) changed its position: not recommended on 7 Aug 2017, restricted by 25 Jun 2019, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for eslicarbazepine, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
5 distinct indication wordings are recorded for eslicarbazepine by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess eslicarbazepine, on 18 Jan 2010; PBAC (Australia) did not open a file until 2021 — an unusually long tail of 11.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
4 of the 5 agencies here assessed eslicarbazepine more than once, SMC (Scotland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed eslicarbazepine.
The full ledger for eslicarbazepine reads 4 recommended, 3 not recommended, 2 restricted and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2021 | Epilepsy | Not recommended | source |
| AWMSG (Wales) | 25 Jun 2019 | Adjunctive therapy in adolescents and children aged above six years, with partial-onset seizures with or without seconda… | recommended with restrictions (limited) | source |
| TLV (Sweden) | 13 Jun 2019 | Zebinix oral suspension ingår i högkostnadsskyddet | general subsidy | source |
| SMC (Scotland) | 11 Jun 2018 | As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. | not recommended | source |
| HAS (France) | 22 Sep 2010 | Listing (Transparency Committee) | ASMR V | source |
6 further decisions for eslicarbazepine, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- zonisamide — divergent outcome (recommended vs other) on a shared indication
- cannabidiol — same ATC class N03A — Antiepileptics
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
Coverage: 11 decisions for eslicarbazepine from 5 agencies, 2010 to 2021. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.